메뉴 건너뛰기




Volumn 17, Issue 3, 1999, Pages 285-311

Antiestrogens - Tamoxifen, SERMs and beyond

Author keywords

Breast cancer; Chemoprevention; ER ; Estrogen receptor; Estrogen related diseases

Indexed keywords

ANTIESTROGEN; CELL NUCLEUS RECEPTOR; EPIDERMAL GROWTH FACTOR; ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SOMATOMEDIN; TAMOXIFEN;

EID: 0033373381     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006348907994     Document Type: Article
Times cited : (117)

References (247)
  • 3
    • 0024317270 scopus 로고
    • The human estrogen receptor has two independent nonacidic transcriptional activation functions
    • Tora L, White J, Brou C, Tassett D, Webster N, Scheer E, Chambon P: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477-487, 1989
    • (1989) Cell , vol.59 , pp. 477-487
    • Tora, L.1    White, J.2    Brou, C.3    Tassett, D.4    Webster, N.5    Scheer, E.6    Chambon, P.7
  • 4
    • 84995870933 scopus 로고
    • Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intranolecular regions
    • Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intranolecular regions. Mot Endocrinol 8: 21-30, 1994
    • (1994) Mot Endocrinol , vol.8 , pp. 21-30
    • Tzukerman, M.T.1    Esty, A.2    Santiso-Mere, D.3    Danielian, P.4    Parker, M.G.5    Stein, R.B.6    Pike, J.W.7    McDonnell, D.P.8
  • 5
    • 0023712331 scopus 로고
    • The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function
    • Webster NJG, Green S, Jin JR, Chambon P: The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54: 199-207, 1988
    • (1988) Cell , vol.54 , pp. 199-207
    • Webster, N.J.G.1    Green, S.2    Jin, J.R.3    Chambon, P.4
  • 6
    • 0025062215 scopus 로고
    • Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen
    • Berry M, Metzger D, Chambon P: Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818, 1990
    • (1990) EMBO J , vol.9 , pp. 2811-2818
    • Berry, M.1    Metzger, D.2    Chambon, P.3
  • 7
    • 0024343546 scopus 로고
    • The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon
    • Webster NJG, Green S, Tasset D, Panglikitmongkol M Chambon P: The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon. EMBO J 8: 1441-1446, 1989
    • (1989) EMBO J , vol.8 , pp. 1441-1446
    • Webster, N.J.G.1    Green, S.2    Tasset, D.3    Panglikitmongkol, M.4    Chambon, P.5
  • 8
    • 0030910962 scopus 로고    scopus 로고
    • Identification of a third autonomous activation domain within the human estrogen receptor
    • Norris JD, Fan DJ, Kerner SA, McDonnell DP: Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 11: 747-754, 1997
    • (1997) Mol Endocrinol , vol.11 , pp. 747-754
    • Norris, J.D.1    Fan, D.J.2    Kerner, S.A.3    McDonnell, D.P.4
  • 10
    • 0030995199 scopus 로고    scopus 로고
    • The estrogen receptor activity cycle: Dependence on multiple protein-protein interactions
    • Lieberman BA: The estrogen receptor activity cycle: dependence on multiple protein-protein interactions. Crit Rev Eukaryotic Gene Expression 7: 43-59, 1997
    • (1997) Crit Rev Eukaryotic Gene Expression , vol.7 , pp. 43-59
    • Lieberman, B.A.1
  • 11
    • 0031932603 scopus 로고    scopus 로고
    • Cross-talk between peptide growth factor and estrogen receptor signaling pathways
    • Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58: 627-632, 1998
    • (1998) Biol Reprod , vol.58 , pp. 627-632
    • Smith, C.L.1
  • 13
    • 0032436976 scopus 로고    scopus 로고
    • Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways
    • Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J: Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55: 5-10, 1998
    • (1998) Oncology , vol.55 , pp. 5-10
    • Kato, S.1    Kitamoto, T.2    Masuhiro, Y.3    Yanagisawa, J.4
  • 14
    • 0032557452 scopus 로고    scopus 로고
    • Estradiol-induced phosphorylation of serine 118 is in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
    • Joel PB, Traish AM, Lannigans DA: Estradiol-induced phosphorylation of serine 118 is in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273: 13317-13323, 1998
    • (1998) J Biol Chem , vol.273 , pp. 13317-13323
    • Joel, P.B.1    Traish, A.M.2    Lannigans, D.A.3
  • 15
    • 0030931670 scopus 로고    scopus 로고
    • Regulation of estrogen receptor transcriptional enhancement by the cyclinA/Cdk2 complex
    • Trowbridge JM, Rogatsky I, Garabedian MJ: Regulation of estrogen receptor transcriptional enhancement by the cyclinA/Cdk2 complex. Proc Natl Acad Sci USA 94: 10132-10137, 1997
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 10132-10137
    • Trowbridge, J.M.1    Rogatsky, I.2    Garabedian, M.J.3
  • 16
    • 0025329841 scopus 로고
    • Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor
    • Fawell SE, Lees JA White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60: 953-962, 1990
    • (1990) Cell , vol.60 , pp. 953-962
    • Fawell, S.E.1    Lees, J.A.2    White, R.3    Parker, M.G.4
  • 17
    • 0023034983 scopus 로고
    • An estrogen responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells
    • Klein-Hitpass L, Schorpp M, Wagner U, Ryffel CU: An estrogen responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46: 1053-1061, 1986
    • (1986) Cell , vol.46 , pp. 1053-1061
    • Klein-Hitpass, L.1    Schorpp, M.2    Wagner, U.3    Ryffel, C.U.4
  • 18
    • 0023808861 scopus 로고
    • The estrogen receptor binds tightly to its response element as a ligand-induced homodimer
    • Kumar V, Chambon P: The estrogen receptor binds tightly to its response element as a ligand-induced homodimer. Cell 55: 145-156, 1988
    • (1988) Cell , vol.55 , pp. 145-156
    • Kumar, V.1    Chambon, P.2
  • 19
    • 0027235507 scopus 로고
    • High affinity binding of the estrogen receptor to a DNA response element does not require homodimer formation or estrogen
    • Furlow JD, Murdoch FE, Gorski J: High affinity binding of the estrogen receptor to a DNA response element does not require homodimer formation or estrogen. J Biol Chem 268: 12519-12525, 1993
    • (1993) J Biol Chem , vol.268 , pp. 12519-12525
    • Furlow, J.D.1    Murdoch, F.E.2    Gorski, J.3
  • 20
    • 0030451142 scopus 로고    scopus 로고
    • Interaction of steroid hormone receptors with the transcription initiation complex
    • Beato M, Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17: 587-609, 1996
    • (1996) Endocr Rev , vol.17 , pp. 587-609
    • Beato, M.1    Sanchez-Pacheco, A.2
  • 24
    • 0029841146 scopus 로고    scopus 로고
    • Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene
    • Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225, 1996
    • (1996) Science , vol.273 , pp. 1222-1225
    • Yang, N.N.1    Venugopalan, M.2    Hardikar, S.3    Glasebrook, A.4
  • 25
    • 0027205024 scopus 로고
    • Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos or c-jun synthesis
    • Philips A, Chalbos D, Rochefort H: Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos or c-jun synthesis. J Biol Chem 268: 14103-14108, 1993
    • (1993) J Biol Chem , vol.268 , pp. 14103-14108
    • Philips, A.1    Chalbos, D.2    Rochefort, H.3
  • 26
    • 0032479304 scopus 로고    scopus 로고
    • Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits
    • Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW: Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273: 16651-16654, 1998
    • (1998) J Biol Chem , vol.273 , pp. 16651-16654
    • Lee, S.K.1    Kim, H.J.2    Na, S.Y.3    Kim, T.S.4    Choi, H.S.5    Im, S.Y.6    Lee, J.W.7
  • 27
    • 0025817801 scopus 로고
    • Dopaminergic and ligand-independent activation of steroid hormone receptors
    • Power RF, Lydon JP, Conneely OM, O'Malley BW: Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 252: 1546-1547, 1991
    • (1991) Science , vol.252 , pp. 1546-1547
    • Power, R.F.1    Lydon, J.P.2    Conneely, O.M.3    O'Malley, B.W.4
  • 28
    • 0030888284 scopus 로고    scopus 로고
    • Estrogen-induced activation of CDK4 and CDK2 during G1>S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-CDK2
    • Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of CDK4 and CDK2 during G(1>S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-CDK2. J Biol Chem 272: 10882-10894, 1997
    • (1997) J Biol Chem , vol.272 , pp. 10882-10894
    • Prall, O.W.J.1    Sarcevic, B.2    Musgrove, E.A.3    Watts, C.K.W.4    Sutherland, R.L.5
  • 30
    • 0028786916 scopus 로고
    • Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
    • Watts CKW, Brady A, Sarcevic B, DeFazio A, Musgrove EA, Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804-1813, 1995
    • (1995) Mol Endocrinol , vol.9 , pp. 1804-1813
    • Watts, C.K.W.1    Brady, A.2    Sarcevic, B.3    DeFazio, A.4    Musgrove, E.A.5    Sutherland, R.L.6
  • 31
    • 0030927929 scopus 로고    scopus 로고
    • Esaogen-dependent cyclin E-CDK2 activation through p21 redistribution
    • Planassilo MD, Weinberg RA: Esaogen-dependent cyclin E-CDK2 activation through p21 redistribution. Mol Cell Biol 17: 4039-4069, 1997
    • (1997) Mol Cell Biol , vol.17 , pp. 4039-4069
    • Planassilo, M.D.1    Weinberg, R.A.2
  • 32
    • 0343618126 scopus 로고    scopus 로고
    • Mechanisms of antiestrogen, progestin/antiprogestin, and retinoid inhibition of cell cycle progression in breast cancer cells
    • Pasqualini JR, Katzenellenbogen BS (eds) Marcel Dekker, New York
    • Watts CKW, Wilcken NRC, Hamilton JA, Sweeney KJE, Musgrove EA, Sutherland RL: Mechanisms of antiestrogen, progestin/antiprogestin, and retinoid inhibition of cell cycle progression in breast cancer cells. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 119-140
    • (1996) Hormone Dependent Cancer , pp. 119-140
    • Watts, C.K.W.1    Wilcken, N.R.C.2    Hamilton, J.A.3    Sweeney, K.J.E.4    Musgrove, E.A.5    Sutherland, R.L.6
  • 33
    • 0028875555 scopus 로고
    • Hormone-dependent regulation of BRCAI in human breast cancer cells
    • Gudas JM, Nguyen H, Li T, Cowan KH: Hormone-dependent regulation of BRCAI in human breast cancer cells. Cancer Res 55: 4561-4565, 1995
    • (1995) Cancer Res , vol.55 , pp. 4561-4565
    • Gudas, J.M.1    Nguyen, H.2    Li, T.3    Cowan, K.H.4
  • 35
    • 0031605753 scopus 로고    scopus 로고
    • Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation
    • Westley BR, Clayton SJ, Daws MR, Molloy CA, May FEB: Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 63: 35-44, 1998
    • (1998) Biochem Soc Symp , vol.63 , pp. 35-44
    • Westley, B.R.1    Clayton, S.J.2    Daws, M.R.3    Molloy, C.A.4    Feb, M.5
  • 37
    • 0029821812 scopus 로고    scopus 로고
    • Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
    • Helle SI, Holly JMP, Tally M, Hall K, Van der Stappen J, Lonning PE: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69: 335-339, 1996
    • (1996) Int J Cancer , vol.69 , pp. 335-339
    • Helle, S.I.1    Jmp, H.2    Tally, M.3    Hall, K.4    Van Der Stappen, J.5    Lonning, P.E.6
  • 38
    • 0026600841 scopus 로고
    • Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors
    • Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025-1033, 1992
    • (1992) EMBO J , vol.11 , pp. 1025-1033
    • Danielian, P.S.1    White, R.2    Lees, J.A.3    Parker, M.G.4
  • 40
    • 0029978077 scopus 로고    scopus 로고
    • Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens
    • Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230-242, 1996
    • (1996) Mol Endocrinol , vol.10 , pp. 230-242
    • Montano, M.M.1    Ekena, K.2    Krueger, K.D.3    Keller, A.L.4    Katzenellenbogen, B.S.5
  • 41
    • 0029073127 scopus 로고
    • Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists
    • Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206-4210, 1995
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 4206-4210
    • Mahfoudi, A.1    Roulet, E.2    Dauvois, S.3    Parker, M.G.4    Wahli, W.5
  • 42
    • 2642593030 scopus 로고    scopus 로고
    • The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
    • Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58: 1872-1875, 1999
    • (1999) Cancer Res , vol.58 , pp. 1872-1875
    • Levenson, A.S.1    Jordan, V.C.2
  • 43
    • 0028233383 scopus 로고
    • Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
    • Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264: 1455-1458, 1994
    • (1994) Science , vol.264 , pp. 1455-1458
    • Halachmi, S.1    Marden, E.2    Martin, G.3    MacKay, H.4    Abbondanza, C.5    Brown, M.6
  • 45
    • 0030949836 scopus 로고    scopus 로고
    • GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
    • Hong H, Kohli K, Garabedian MJ, Stallcup MR: GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17: 2735-2744, 1997
    • (1997) Mol Cell Biol , vol.17 , pp. 2735-2744
    • Hong, H.1    Kohli, K.2    Garabedian, M.J.3    Stallcup, M.R.4
  • 46
    • 0030946198 scopus 로고    scopus 로고
    • Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
    • Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen, Mol Endocrinoi 11:657-666, 1997
    • (1997) Mol Endocrinoi , vol.11 , pp. 657-666
    • Smith, C.L.1    Nawaz, Z.2    O'Malley, B.W.3
  • 47
    • 0031611355 scopus 로고    scopus 로고
    • Transcriptional activation by oestrogen receptors
    • Parker MG: Transcriptional activation by oestrogen receptors. Biochem Soc Symp 63: 45-50, 1998
    • (1998) Biochem Soc Symp , vol.63 , pp. 45-50
    • Parker, M.G.1
  • 49
    • 0032524634 scopus 로고    scopus 로고
    • The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation functionn 1 (AF1) and AF2 domains of steroid receptors
    • Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW: The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation functionn 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273: 12101-12108, 1998
    • (1998) J Biol Chem , vol.273 , pp. 12101-12108
    • Onate, S.A.1    Boonyaratanakornkit, V.2    Spencer, T.E.3    Tsai, S.Y.4    Tsai, M.J.5    Edwards, D.P.6    O'Malley, B.W.7
  • 50
    • 0030998328 scopus 로고    scopus 로고
    • The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
    • Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11: 693-705, 1997
    • (1997) Mol Endocrinol , vol.11 , pp. 693-705
    • Jackson, T.A.1    Richer, J.K.2    Bain, D.L.3    Takimoto, G.S.4    Tung, L.5    Horwitz, K.B.6
  • 51
    • 0030333304 scopus 로고    scopus 로고
    • Epidemiology of susceptibility to breast cancer
    • Hulka BS: Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res 395: 159-174, 1996
    • (1996) Prog Clin Biol Res , vol.395 , pp. 159-174
    • Hulka, B.S.1
  • 52
    • 0021132874 scopus 로고
    • Correlation between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
    • Clark GM, Osborne CK, McGuire WL: Correlation between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102-1109, 1984
    • (1984) J Clin Oncol , vol.2 , pp. 1102-1109
    • Clark, G.M.1    Osborne, C.K.2    McGuire, W.L.3
  • 53
    • 50549123220 scopus 로고
    • On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
    • Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2: 104-107, 1896
    • (1896) Lancet , vol.2 , pp. 104-107
    • Beatson, G.T.1
  • 54
    • 0343618100 scopus 로고
    • The role of major endocrine ablation
    • Stoll BA (ed) Yearbook Medical Publishers, Chicago
    • Robin PE, Dalton GA: The role of major endocrine ablation, In: Stoll BA (ed) Breast Cancer Early and Late. Yearbook Medical Publishers, Chicago, 1977, pp 147-156
    • (1977) Breast Cancer Early and Late , pp. 147-156
    • Robin, P.E.1    Dalton, G.A.2
  • 56
    • 0020617897 scopus 로고
    • Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells
    • Sutherland RL, Hall RE, Taylor JW: Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43: 3998-4006, 1983
    • (1983) Cancer Res , vol.43 , pp. 3998-4006
    • Sutherland, R.L.1    Hall, R.E.2    Taylor, J.W.3
  • 57
    • 0020606637 scopus 로고
    • Effects of tamoxifen on human breast cancer cell kinetics: Accumulation of cells in early G1 phase
    • Osborne CK, Boldt DH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583-3585, 1983
    • (1983) Cancer Res , vol.43 , pp. 3583-3585
    • Osborne, C.K.1    Boldt, D.H.2    Clark, G.M.3    Trent, J.M.4
  • 59
    • 0029560348 scopus 로고
    • Relationship between tamoxifen-induced transforming growth factor b1 expression cytostasis and apoptosis in human breast cancer cells
    • Perry RR, Kang Y, Greaves BR: Relationship between tamoxifen-induced transforming growth factor b1 expression cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446, 1995
    • (1995) Br J Cancer , vol.72 , pp. 1441-1446
    • Perry, R.R.1    Kang, Y.2    Greaves, B.R.3
  • 60
    • 0023625418 scopus 로고
    • Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells
    • Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987
    • (1987) Cell , vol.48 , pp. 417-428
    • Knabbe, C.1    Lippman, M.E.2    Wakefield, L.M.3    Flanders, K.C.4    Kasid, A.5    Derynck, R.6    Dickson, R.B.7
  • 61
    • 0027373251 scopus 로고
    • Regulation of the levels of three transforming growth factor mRNAs by estrogen and their effects on the proliferation of human breast cancer cells
    • Jeng MH, Ten Dijke P, Iwata KK, Jordan VC: Regulation of the levels of three transforming growth factor mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 97: 115-123, 1993
    • (1993) Mol Cell Endocrinol , vol.97 , pp. 115-123
    • Jeng, M.H.1    Ten Dijke, P.2    Iwata, K.K.3    Jordan, V.C.4
  • 62
    • 0030849605 scopus 로고    scopus 로고
    • Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in breast cancer cells
    • Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in breast cancer cells. Cancer Res 57: 2606-2610, 1997
    • (1997) Cancer Res , vol.57 , pp. 2606-2610
    • Guvakova, M.A.1    Surmacz, E.2
  • 63
    • 0026591060 scopus 로고
    • Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro
    • Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318-321, 1992
    • (1992) Eur J Cancer , vol.28 , pp. 318-321
    • Antoniotti, S.1    Maggiora, P.2    Dati, C.3    De Bortoli, M.4
  • 64
    • 0030060967 scopus 로고    scopus 로고
    • Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor(IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins
    • Kleinman D, Karas M, Danilenko M, Arbeli A, Roberts CT, Jr., LeRoith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor(IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137: 1089-1095, 1996
    • (1996) Endocrinology , vol.137 , pp. 1089-1095
    • Kleinman, D.1    Karas, M.2    Danilenko, M.3    Arbeli, A.4    Roberts C.T., Jr.5    LeRoith, D.6    Levy, J.7    Sharoni, Y.8
  • 65
    • 0017078344 scopus 로고
    • Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas
    • Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas. Eur J Cancer 12: 419-424, 1976
    • (1976) Eur J Cancer , vol.12 , pp. 419-424
    • Jordan, V.C.1
  • 66
    • 0023229345 scopus 로고
    • The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
    • Gottardis MM, Jordan VC: The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020-4024, 1987
    • (1987) Cancer Res , vol.47 , pp. 4020-4024
    • Gottardis, M.M.1    Jordan, V.C.2
  • 67
    • 0027432309 scopus 로고
    • Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780
    • Huynh HT, Pollak M: Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-5588, 1993
    • (1993) Cancer Res , vol.53 , pp. 5585-5588
    • Huynh, H.T.1    Pollak, M.2
  • 68
    • 0029794465 scopus 로고    scopus 로고
    • Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen
    • Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56: 3954-3960, 1996
    • (1996) Cancer Res , vol.56 , pp. 3954-3960
    • Hyder, S.M.1    Stancel, G.M.2    Chiappetta, C.3    Murthy, L.4    Boettger-Tong, H.L.5    Makela, S.6
  • 69
    • 0027325188 scopus 로고
    • Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer
    • Noguchi S, Motomura K, Inaji Y Imaoka S, Koyama H: Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer. Cancer 72: 131-136, 1993
    • (1993) Cancer , vol.72 , pp. 131-136
    • Noguchi, S.1    Motomura, K.2    Inaji, Y.3    Imaoka, S.4    Koyama, H.5
  • 71
    • 0027475326 scopus 로고
    • Up-regulation of estrogen receptor by tamoxifen in human breast cancer
    • Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H: Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71: 1266-1272, 1993
    • (1993) Cancer , vol.71 , pp. 1266-1272
    • Noguchi, S.1    Motomura, K.2    Inaji, H.3    Imaoka, S.4    Koyama, H.5
  • 72
    • 0031881602 scopus 로고    scopus 로고
    • Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
    • Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48: 11-20, 1998
    • (1998) Breast Cancer Res Treat , vol.48 , pp. 11-20
    • Makris, A.1    Powles, T.J.2    Allred, D.C.3    Ashley, S.4    Ormerod, M.G.5    Titley, J.C.6    Dowsett, M.7
  • 73
    • 0026667688 scopus 로고
    • Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase
    • Newton CJ, Butta A, Nicholls J, Dowsett M: Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase. J Steroid Biochem Mol Biol 42: 891-900, 1992
    • (1992) J Steroid Biochem Mol Biol , vol.42 , pp. 891-900
    • Newton, C.J.1    Butta, A.2    Nicholls, J.3    Dowsett, M.4
  • 74
    • 0019157188 scopus 로고
    • Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites
    • Wakeling AE, Slater SR: Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep 64: 741-744, 1980
    • (1980) Cancer Treat Rep , vol.64 , pp. 741-744
    • Wakeling, A.E.1    Slater, S.R.2
  • 75
    • 0021618186 scopus 로고
    • The pharmacology and clinical uses of tamoxifen
    • Furr BS, Jordan VC: The pharmacology and clinical uses of tamoxifen. Phannacol Ther 25: 127-205, 1984
    • (1984) Phannacol Ther , vol.25 , pp. 127-205
    • Furr, B.S.1    Jordan, V.C.2
  • 76
    • 0015915672 scopus 로고
    • Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
    • Ward HWC: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13-14, 1973
    • (1973) Br Med J , vol.1 , pp. 13-14
    • Ward, H.W.C.1
  • 77
    • 0017565317 scopus 로고
    • Tamoxifen (antiestrogen) therapy in advanced breast cancer
    • Kiang DT, Kennedy BJ: Tamoxifen (antiestrogen) therapy in advanced breast cancer. Am Intern Med 87: 687-690, 1977
    • (1977) Am Intern Med , vol.87 , pp. 687-690
    • Kiang, D.T.1    Kennedy, B.J.2
  • 78
    • 9844266794 scopus 로고    scopus 로고
    • A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
    • Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J, Eastern European Study group: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251-262, 1997
    • (1997) Breast Cancer Res Treat , vol.45 , pp. 251-262
    • Gershanovich, M.1    Garin, A.2    Baltina, D.3    Kurvet, A.4    Kangas, L.5    Ellmen, J.6
  • 79
    • 0031054478 scopus 로고    scopus 로고
    • Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials
    • Kuss JT, Muss HB, Hoen H, Case LD: Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42: 265-274, 1997
    • (1997) Breast Cancer Res Treat , vol.42 , pp. 265-274
    • Kuss, J.T.1    Muss, H.B.2    Hoen, H.3    Case, L.D.4
  • 82
    • 0028360192 scopus 로고
    • ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
    • Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144, 1994
    • (1994) Cancer Lett , vol.81 , pp. 137-144
    • Borg, Å.1    Baldetorp, B.2    Fernö, M.3    Killander, D.4    Olsson, H.5    Rydén, S.6    Sigurdsson, H.7
  • 83
    • 0032982818 scopus 로고    scopus 로고
    • Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
    • Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999
    • (1999) Br J Cancer , vol.79 , pp. 1220-1226
    • Houston, S.J.1    Plunkett, T.A.2    Barnes, D.M.3    Smith, P.4    Rubens, R.D.5    Miles, D.W.6
  • 85
    • 0029021196 scopus 로고
    • Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recwrrent breast cancer
    • Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recwrrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995
    • (1995) J Natl Cancer Inst , vol.87 , pp. 751-756
    • Foekens, J.A.1    Look, M.P.2    Peters, H.A.3    Van Putten, W.L.J.4    Portengen, H.5    Klijn, J.G.M.6
  • 87
    • 0030860567 scopus 로고    scopus 로고
    • Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer
    • Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997
    • (1997) Clin Cancer Res , vol.3 , pp. 1643-1651
    • Newby, J.C.1    Johnston, S.2    Smith, I.E.3    Dowsett, M.4
  • 90
    • 0029781863 scopus 로고    scopus 로고
    • Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
    • Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-2589, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2584-2589
    • Kuukasjärvi, T.1    Kononen, J.2    Helin, H.3    Holli, K.4    Isola, J.5
  • 91
    • 0032537396 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
    • (1998) Lancet , vol.351 , pp. 1451-1467
  • 94
    • 0032508294 scopus 로고    scopus 로고
    • Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
    • Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101, 1998
    • (1998) Lancet , vol.352 , pp. 98-101
    • Powles, T.1    Eeles, R.2    Ashley, S.3    Easton, D.4    Chang, J.5    Dowsett, M.6    Tidy, A.7    Viggers, J.8    Davey, J.9
  • 95
    • 0032508293 scopus 로고    scopus 로고
    • Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomized women
    • Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomized women. Lancet 352: 93-97, 1998
    • (1998) Lancet , vol.352 , pp. 93-97
    • Veronesi, U.1    Maisonneuve, P.2    Costa, A.3    Sacchini, V.4    Maltoni, C.5    Robertson, C.6    Rotmensz, N.7    Boyle, P.8
  • 96
    • 0021356677 scopus 로고
    • The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer
    • Gotfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853-857, 1984
    • (1984) Cancer , vol.53 , pp. 853-857
    • Gotfredsen, A.1    Christiansen, C.2    Palshof, T.3
  • 97
    • 0032508227 scopus 로고    scopus 로고
    • Is tamoxifen effective in prevention of breast cancer?
    • Pritchard KI: Is tamoxifen effective in prevention of breast cancer? Lancet 352: 80-81, 1998
    • (1998) Lancet , vol.352 , pp. 80-81
    • Pritchard, K.I.1
  • 98
    • 0030792818 scopus 로고    scopus 로고
    • Innuence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
    • Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: Innuence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-441, 1997
    • (1997) Cancer , vol.80 , pp. 435-441
    • Karp, S.E.1    Tonin, P.N.2    Begin, L.R.3    Martinez, J.J.4    Zhang, J.C.5    Pollak, M.N.6    Foulkes, W.D.7
  • 99
    • 0032528215 scopus 로고    scopus 로고
    • Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
    • Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310-319, 1998
    • (1998) Cancer , vol.83 , pp. 310-319
    • Loman, N.1    Johannsson, O.2    Bendahl, P.O.3    Borg, A.4    Ferno, M.5    Olsson, H.6
  • 100
    • 0025936010 scopus 로고
    • Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent
    • Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491, 1991
    • (1991) J Natl Cancer Inst , vol.83 , pp. 1488-1491
    • Jordan, V.C.1    Fritz, N.F.2    Langan-Fahey, S.3    Thompson, M.4    Tormey, D.C.5
  • 101
    • 0017190910 scopus 로고
    • Effects of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
    • Groom GV, Griffiths K: Effects of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70: 421-428, 1976
    • (1976) J Endocrinol , vol.70 , pp. 421-428
    • Groom, G.V.1    Griffiths, K.2
  • 102
    • 0342460593 scopus 로고    scopus 로고
    • Ambiguous genitalia in infant exposed to tamoxifen in utero
    • Tewari K, Bonebrake RG, Asrat T, Shanberg AM: Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350: 183-183, 1997
    • (1997) Lancet , vol.350 , pp. 183-183
    • Tewari, K.1    Bonebrake, R.G.2    Asrat, T.3    Shanberg, A.M.4
  • 103
    • 0032941053 scopus 로고    scopus 로고
    • Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients
    • Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, Beyth Y: Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 72: 202-207, 1999
    • (1999) Gynecol Oncol , vol.72 , pp. 202-207
    • Cohen, I.1    Figer, A.2    Tepper, R.3    Shapira, J.4    Altaras, M.M.5    Yigael, D.6    Beyth, Y.7
  • 105
    • 0023146033 scopus 로고
    • Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
    • Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47: 624-630, 1987
    • (1987) Cancer Res , vol.47 , pp. 624-630
    • Jordan, V.C.1    Fritz, N.F.2    Tormey, D.C.3
  • 107
  • 108
    • 0026779758 scopus 로고
    • Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients
    • Lonning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719-4723, 1992
    • (1992) Cancer Res , vol.52 , pp. 4719-4723
    • Lonning, P.E.1    Hall, K.2    Aakvaag, A.3    Lien, E.A.4
  • 111
    • 0030070093 scopus 로고    scopus 로고
    • Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
    • Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 78-84
    • Powles, T.J.1    Hickish, T.2    Kanis, J.A.3    Tidy, A.4    Ashley, S.5
  • 112
    • 0028000253 scopus 로고
    • Effects of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment
    • Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ: Effects of tamoxifen on cardiovascular risk factors in post-menopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539, 1995
    • (1995) J Natl Cancer Inst , vol.86 , pp. 1534-1539
    • Love, R.R.1    Wiebe, D.A.2    Feyzi, J.M.3    Newcomb, P.A.4    Chappell, R.J.5
  • 114
    • 0027325734 scopus 로고
    • Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen: The Stockholm Breast Cancer Study Group
    • Rutquist LE, Matteson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen: the Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85: 1398-1406, 1993
    • (1993) J Natl Cancer Inst , vol.85 , pp. 1398-1406
    • Rutquist, L.E.1    Matteson, A.2
  • 115
    • 0025343030 scopus 로고
    • Effects of tamoxifen treatment on plasma lipids and lipoprotein composition
    • Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 70: 1132-1135, 1990
    • (1990) J Clin Endocrinol Metab , vol.70 , pp. 1132-1135
    • Bagdade, J.D.1    Wolter, J.2    Subbaiah, P.V.3    Ryan, W.4
  • 116
    • 0021238933 scopus 로고
    • Serum lipoprotein and proteins after breast cancer surgery and effects of tamoxifen
    • Rossner S, Wallgren A: Serum lipoprotein and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53: 339-346, 1984
    • (1984) Atherosclerosis , vol.53 , pp. 339-346
    • Rossner, S.1    Wallgren, A.2
  • 118
    • 0026595133 scopus 로고
    • Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
    • Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85, 1992
    • (1992) Lancet , vol.339 , pp. 71-85
  • 119
    • 0032542924 scopus 로고    scopus 로고
    • Tamoxifen for the prevention of breast cancer -important questions remain unanswered, and existing trials should continue
    • Bruzzi P: Tamoxifen for the prevention of breast cancer -important questions remain unanswered, and existing trials should continue. Br Med J 316: 1181-1182, 1998
    • (1998) Br Med J , vol.316 , pp. 1181-1182
    • Bruzzi, P.1
  • 122
    • 0026606580 scopus 로고
    • Induction of covalent DNA adducts in rodents by tamoxifen
    • Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992
    • (1992) Cancer Res , vol.52 , pp. 1360-1363
    • Han, X.1    Liehr, J.G.2
  • 123
    • 0029745072 scopus 로고    scopus 로고
    • Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
    • Hemminki K, Rajaniemi H, Lindahl B, Moberger B: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56: 4374-4377, 1996
    • (1996) Cancer Res , vol.56 , pp. 4374-4377
    • Hemminki, K.1    Rajaniemi, H.2    Lindahl, B.3    Moberger, B.4
  • 124
    • 0030899189 scopus 로고    scopus 로고
    • Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
    • Li DH, Dragan Y, Jordan VC, Wang MY, Pitot HC: Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 57: 1438-1441, 1997
    • (1997) Cancer Res , vol.57 , pp. 1438-1441
    • Li, D.H.1    Dragan, Y.2    Jordan, V.C.3    Wang, M.Y.4    Pitot, H.C.5
  • 125
    • 0033135051 scopus 로고    scopus 로고
    • Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen
    • Terashima I, Suzuki N, Shibutani S: Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091-2095, 1999
    • (1999) Cancer Res , vol.59 , pp. 2091-2095
    • Terashima, I.1    Suzuki, N.2    Shibutani, S.3
  • 126
    • 0027412216 scopus 로고
    • High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients
    • Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485-490, 1993
    • (1993) J Clin Oncol , vol.11 , pp. 485-490
    • Magriples, U.1    Naftolin, F.2    Schwartz, P.E.3    Carcangiu, M.L.4
  • 127
    • 0028287647 scopus 로고
    • Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
    • Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994
    • (1994) Lancet , vol.343 , pp. 1318-1321
    • Kedar, R.P.1    Bourne, T.H.2    Powles, T.J.3    Collins, W.P.4    Ashley, S.E.5    Cosgrove, D.O.6    Campbell, S.7
  • 128
    • 0031052184 scopus 로고    scopus 로고
    • Tamoxifen and endometrial cancer: Tamoxifen effects on the human female genital tract
    • Cohen CJ: Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 24: S1-55-S1-64, 1997
    • (1997) Semin Oncol , vol.24
    • Cohen, C.J.1
  • 131
    • 0031214148 scopus 로고    scopus 로고
    • Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients
    • Cheng WF, Lin HH, Torng PL, Huang SC: Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66: 233-237, 1997
    • (1997) Gynecol Oncol , vol.66 , pp. 233-237
    • Cheng, W.F.1    Lin, H.H.2    Torng, P.L.3    Huang, S.C.4
  • 134
    • 0031746719 scopus 로고    scopus 로고
    • Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy
    • McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178: 1145-1150, 1998
    • (1998) Am J Obstet Gynecol , vol.178 , pp. 1145-1150
    • McGonigle, K.F.1    Shaw, S.L.2    Vasilev, S.A.3    Odom-Maryon, T.4    Roy, S.5    Simpson, J.F.6
  • 138
    • 0019319147 scopus 로고
    • Tamoxifen and thromboembolism
    • Hendrick A, Sebramanian VP: Tamoxifen and thromboembolism. JAMA 243: 514-515, 1980
    • (1980) JAMA , vol.243 , pp. 514-515
    • Hendrick, A.1    Sebramanian, V.P.2
  • 140
    • 0027998596 scopus 로고
    • Protein S and protein C level changes with adjuvant tamoxifen therapy in post-menopausal women
    • Mamby CC, Love RR, Feyzi JM: Protein S and protein C level changes with adjuvant tamoxifen therapy in post-menopausal women. Breast Cancer Res Treat 30: 311-314, 1994
    • (1994) Breast Cancer Res Treat , vol.30 , pp. 311-314
    • Mamby, C.C.1    Love, R.R.2    Feyzi, J.M.3
  • 141
    • 0021255302 scopus 로고
    • Tamoxifen treatment of metastatic breast cancer and antithrombin III levels
    • Enck RE, Rios CM; Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607-2609, 1984
    • (1984) Cancer , vol.53 , pp. 2607-2609
    • Enck, R.E.1    Rios, C.M.2
  • 142
    • 0023868350 scopus 로고
    • Effects of tamoxifen in blood coagulation
    • Auger MJ, Mackle MJ: Effects of tamoxifen in blood coagulation. Cancer 61: 1316-1319, 1988
    • (1988) Cancer , vol.61 , pp. 1316-1319
    • Auger, M.J.1    Mackle, M.J.2
  • 143
    • 0029995266 scopus 로고    scopus 로고
    • Tamoxifen-associated eye disease: A review
    • Mayfield SG, Gorin MB: Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 1018-1026, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 1018-1026
    • Mayfield, S.G.1    Gorin, M.B.2
  • 144
    • 0023760993 scopus 로고
    • Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
    • Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187, 1988
    • (1988) Cancer Res , vol.48 , pp. 5183-5187
    • Gottardis, M.M.1    Jordan, V.C.2
  • 150
    • 0030734795 scopus 로고    scopus 로고
    • Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction
    • Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA: Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36: 14897-14905, 1997
    • (1997) Biochemistry , vol.36 , pp. 14897-14905
    • Carlson, K.E.1    Choi, I.2    Gee, A.3    Katzenellenbogen, B.S.4    Katzenellenbogen, J.A.5
  • 151
    • 0032031082 scopus 로고    scopus 로고
    • Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens
    • Tremblay GB, Tremblay A, Labrie F, Giguere V: Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res 58: 877-881, 1998
    • (1998) Cancer Res , vol.58 , pp. 877-881
    • Tremblay, G.B.1    Tremblay, A.2    Labrie, F.3    Giguere, V.4
  • 153
    • 0027219768 scopus 로고
    • Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples
    • Murphy LC, Dotzlaw H, Hamerton J, Schwarz J: Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res Treat 26: 149-161, 1993
    • (1993) Breast Cancer Res Treat , vol.26 , pp. 149-161
    • Murphy, L.C.1    Dotzlaw, H.2    Hamerton, J.3    Schwarz, J.4
  • 156
    • 0027146672 scopus 로고
    • Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line
    • Castles CG, Fuqua SAW, Klotz DM, Hill SM: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 53: 5934-5939, 1993
    • (1993) Cancer Res , vol.53 , pp. 5934-5939
    • Castles, C.G.1    Fuqua, S.A.W.2    Klotz, D.M.3    Hill, S.M.4
  • 158
    • 0029738763 scopus 로고    scopus 로고
    • Prevalence of estrogen receptor variant messenger RNAs in human breast cancer
    • Leygue E, Huang AH Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 56: 4324-4327, 1996
    • (1996) Cancer Res , vol.56 , pp. 4324-4327
    • Leygue, E.1    Huang, A.H.2    Murphy, L.C.3    Watson, P.H.4
  • 159
    • 0030292856 scopus 로고    scopus 로고
    • Multiple splicing variants of the estrogen receptor are present in individual human breast tumors
    • Zhang QX, Hilsenbeck SG, Fuqua SAW, Borg A: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 59: 251-260, 1996
    • (1996) J Steroid Biochem Mol Biol , vol.59 , pp. 251-260
    • Zhang, Q.X.1    Hilsenbeck, S.G.2    Fuqua, S.A.W.3    Borg, A.4
  • 160
    • 0028795855 scopus 로고
    • Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer
    • Daffada AAI, Johnston SRD, Smith EE, Detre S, King N, Dowsett M: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 55: 288-293, 1995
    • (1995) Cancer Res , vol.55 , pp. 288-293
    • Daffada, A.A.I.1    Johnston, S.R.D.2    Smith, E.E.3    Detre, S.4    King, N.5    Dowsett, M.6
  • 161
    • 0028049163 scopus 로고
    • Characterization of ligand-dependent phosphorylation of the estrogen receptor
    • Lahooti H, White R, Danielian PS, Parker MG: Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8: 182-188, 1994
    • (1994) Mol Endocrinol , vol.8 , pp. 182-188
    • Lahooti, H.1    White, R.2    Danielian, P.S.3    Parker, M.G.4
  • 162
    • 0028800721 scopus 로고
    • Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor
    • Astruc ME, Chabret C, Bali P, Gagne D, Pens M: Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor. Endocrinology 136: 824-832, 1995
    • (1995) Endocrinology , vol.136 , pp. 824-832
    • Astruc, M.E.1    Chabret, C.2    Bali, P.3    Gagne, D.4    Pens, M.5
  • 163
    • 0029802492 scopus 로고    scopus 로고
    • Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
    • Dumont JA, Bitoni AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351-359, 1996
    • (1996) Cell Growth Differ , vol.7 , pp. 351-359
    • Dumont, J.A.1    Bitoni, A.J.2    Wallace, C.D.3    Baumann, R.J.4    Cashman, E.A.5    Cross-Doersen, D.E.6
  • 164
    • 0033049975 scopus 로고    scopus 로고
    • Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
    • Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251-256, 1999
    • (1999) Clin Cancer Res , vol.5 , pp. 251-256
    • Johnston, S.R.D.1    Lu, B.2    Scott, G.K.3    Kushner, P.J.4    Smith, I.E.5    Dowsett, M.6    Benz, C.C.7
  • 165
  • 166
    • 0026068370 scopus 로고
    • Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
    • Osborne CK, Coronado E, Alfred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482, 1991
    • (1991) J Natl Cancer Inst , vol.83 , pp. 1477-1482
    • Osborne, C.K.1    Coronado, E.2    Alfred, D.C.3    Wiebe, V.4    DeGregorio, M.5
  • 167
    • 0026580111 scopus 로고
    • Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients
    • Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304-310, 1992
    • (1992) J Clin Oncol , vol.10 , pp. 304-310
    • Osborne, C.K.1    Wiebe, V.J.2    McGuire, W.L.3    Ciocca, D.R.4    DeGregorio, M.W.5
  • 168
    • 0026632964 scopus 로고
    • Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors
    • Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990-994, 1992
    • (1992) J Clin Oncol , vol.10 , pp. 990-994
    • Wiebe, V.J.1    Osborne, C.K.2    McGuire, W.L.3    DeGregorio, M.W.4
  • 169
    • 0027280831 scopus 로고
    • Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites
    • Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806-812, 1993
    • (1993) J Natl Cancer Inst , vol.85 , pp. 806-812
    • Wolf, D.M.1    Langan-Fahey, S.M.2    Parker, C.J.3    McCague, R.4    Jordan, V.C.5
  • 171
    • 0025251643 scopus 로고
    • Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
    • Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883-888, 1990
    • (1990) Eur J Cancer , vol.26 , pp. 883-888
    • Langan-Fahey, S.M.1    Tormey, D.C.2    Jordan, V.C.3
  • 172
    • 0027185314 scopus 로고
    • Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site
    • Dorssers LCJ, van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM: Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7: 870-878, 1993
    • (1993) Mol Endocrinol , vol.7 , pp. 870-878
    • Dorssers, L.C.J.1    Van Agthoven, T.2    Dekker, A.3    Van Agthoven, T.L.A.4    Kok, E.M.5
  • 173
    • 0032525138 scopus 로고    scopus 로고
    • Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells
    • van Agthoven T, Van Agthoven TLA, Dekker A, van der Spek PJ, Vreede L, Dorssers LCJ: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799-2808, 1998
    • (1998) EMBO J , vol.17 , pp. 2799-2808
    • Van Agthoven, T.1    Van Agthoven, T.L.A.2    Dekker, A.3    Van Der Spek, P.J.4    Vreede, L.5    Dorssers, L.C.J.6
  • 174
    • 0031026744 scopus 로고    scopus 로고
    • Clinical potential of new anti-estrogens
    • Gradishar WJ, Jordan VC: Clinical potential of new anti-estrogens. J Clin Oncol 15: 840-852, 1997
    • (1997) J Clin Oncol , vol.15 , pp. 840-852
    • Gradishar, W.J.1    Jordan, V.C.2
  • 175
    • 0032126037 scopus 로고    scopus 로고
    • In search of the perfect SERM: Beyond tamoxifen and raloxifene
    • McNeil C: In search of the perfect SERM: Beyond tamoxifen and raloxifene. J Natl Cancer Inst 90: 956-957, 1998
    • (1998) J Natl Cancer Inst , vol.90 , pp. 956-957
    • McNeil, C.1
  • 177
    • 0027428568 scopus 로고
    • Major differences in the hep-atocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats
    • Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM: Major differences in the hep-atocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53: 4534-4541, 1993
    • (1993) Cancer Res , vol.53 , pp. 4534-4541
    • Hard, G.C.1    Iatropoulos, M.J.2    Jordan, K.3    Radi, L.4    Kaltenberg, O.P.5    Imondi, A.R.6    Williams, G.M.7
  • 180
    • 0027409546 scopus 로고
    • Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
    • Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11: 345-350, 1993
    • (1993) J Clin Oncol , vol.11 , pp. 345-350
    • Vogel, C.L.1    Shemano, I.2    Schoenfelder, J.3    Gams, R.A.4    Green, M.R.5
  • 182
    • 0028793801 scopus 로고
    • Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
    • Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59: 241-266, 1995
    • (1995) Gynecol Oncol , vol.59 , pp. 241-266
    • Tomas, E.1    Kauppila, A.2    Blanco, G.3    Apaja-Sarkkinen, M.4    Laatikainen, T.5
  • 183
    • 0032052776 scopus 로고    scopus 로고
    • Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations
    • Tonetti DA, O'Regan R, Tanjore S, England G, Jordan VC: Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations. J Steroid Biochem Mol Biol 65: 181-189, 1998
    • (1998) J Steroid Biochem Mol Biol , vol.65 , pp. 181-189
    • Tonetti, D.A.1    O'Regan, R.2    Tanjore, S.3    England, G.4    Jordan, V.C.5
  • 184
    • 0031764190 scopus 로고    scopus 로고
    • Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
    • Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83: 1158-1162, 1998
    • (1998) J Clin Endocrinol Metab , vol.83 , pp. 1158-1162
    • Marttunen, M.B.1    Hietanen, P.2    Tiitinen, A.3    Ylikorkala, O.4
  • 185
    • 0031962302 scopus 로고    scopus 로고
    • Tamoxifen and tamoxifene in breast cancer: Comparison of safety and efficacy
    • Buzdar AU, Hortobagyi GN: Tamoxifen and tamoxifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16: 348-353, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 348-353
    • Buzdar, A.U.1    Hortobagyi, G.N.2
  • 186
    • 0028170305 scopus 로고
    • Preclinical data for droloxifene
    • Hasmann M, Rattel B, Loser R: Preclinical data for droloxifene. Cancer Lett 84: 101-116, 1994
    • (1994) Cancer Lett , vol.84 , pp. 101-116
    • Hasmann, M.1    Rattel, B.2    Loser, R.3
  • 187
    • 0028068906 scopus 로고
    • Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
    • Rauschning W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31: 83-94, 1994
    • (1994) Breast Cancer Res Treat , vol.31 , pp. 83-94
    • Rauschning, W.1    Pritchard, K.I.2
  • 188
    • 0026345105 scopus 로고
    • Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
    • Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851-5858, 1991
    • (1991) Cancer Res , vol.51 , pp. 5851-5858
    • Chander, S.K.1    McCague, R.2    Luqmani, Y.3    Newton, C.4    Dowsett, M.5    Jarman, M.6    Coombes, R.C.7
  • 189
    • 0030750807 scopus 로고    scopus 로고
    • Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts
    • Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC: Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 76: 700-704, 1997
    • (1997) Br J Cancer , vol.76 , pp. 700-704
    • Pace, P.1    Jarman, M.2    Phillips, D.3    Hewer, A.4    Bliss, J.5    Coombes, R.C.6
  • 190
    • 0031039798 scopus 로고    scopus 로고
    • The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
    • Johnston SRD, Riddler S, Haynes BP, A'Hern R, Smith IE, Jarman M, Dowsett M: The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer 75: 804-809, 1997
    • (1997) Br J Cancer , vol.75 , pp. 804-809
    • Johnston, S.R.D.1    Riddler, S.2    Haynes, B.P.3    A'Hern, R.4    Smith, I.E.5    Jarman, M.6    Dowsett, M.7
  • 192
    • 0027279120 scopus 로고
    • MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
    • Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993
    • (1993) Cancer Res , vol.53 , pp. 3229-3232
    • Brünner, N.1    Frandsen, T.L.2    Holst-Hansen, C.3    Bei, M.4    Thompson, E.W.5    Wakeling, A.E.6    Lippman, M.E.7    Clarke, R.8
  • 193
    • 0024319781 scopus 로고
    • Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
    • Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093, 1989
    • (1989) Cancer Res , vol.49 , pp. 4090-4093
    • Gottardis, M.M.1    Jiang, S.Y.2    Jeng, M.H.3    Jordan, V.C.4
  • 195
    • 0032912182 scopus 로고    scopus 로고
    • Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
    • Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81: 299-304, 1999
    • (1999) Int J Cancer , vol.81 , pp. 299-304
    • Salerno, M.1    Sisci, D.2    Mauro, L.3    Guvakova, M.A.4    Ando, S.5    Surmacz, E.6
  • 196
  • 197
    • 0031730275 scopus 로고    scopus 로고
    • Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia
    • Sibonga JD, Dobnig H, Harden RM, Turner RT: Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139: 3736-3742, 1998
    • (1998) Endocrinology , vol.139 , pp. 3736-3742
    • Sibonga, J.D.1    Dobnig, H.2    Harden, R.M.3    Turner, R.T.4
  • 198
    • 0020582094 scopus 로고
    • Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
    • Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2875, 1983
    • (1983) Life Sci , vol.32 , pp. 2875
    • Clemens, J.A.1    Bennett, D.R.2    Black, L.J.3    Jones, C.D.4
  • 199
  • 201
  • 203
    • 0002258194 scopus 로고    scopus 로고
    • Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
    • Abstract
    • Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, Glusman J, Krueger K: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 17: 2a(Abstract), 1998
    • (1998) Proc am Soc Clin Oncol , vol.17
    • Cummings, S.R.1    Norton, L.2    Eckert, S.3    Grady, D.4    Cauley, J.5    Knickerbocker, R.6    Black, D.M.7    Nickelsen, T.8    Glusman, J.9    Krueger, K.10
  • 206
    • 0031813087 scopus 로고    scopus 로고
    • Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)
    • Luo SQ, Labrie C, Belanger A, Candas B, Labrie F: Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050). Breast Cancer Res Treat 49: 1-11, 1998
    • (1998) Breast Cancer Res Treat , vol.49 , pp. 1-11
    • Luo, S.Q.1    Labrie, C.2    Belanger, A.3    Candas, B.4    Labrie, F.5
  • 207
    • 0030879732 scopus 로고    scopus 로고
    • Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro
    • Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, Labrie F: Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 73: 104-112, 1997
    • (1997) Int J Cancer , vol.73 , pp. 104-112
    • Simard, J.1    Labrie, C.2    Belanger, A.3    Gauthier, S.4    Singh, S.M.5    Merand, Y.6    Labrie, F.7
  • 208
    • 0031964105 scopus 로고    scopus 로고
    • Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice
    • Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F: Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 58: 60-64, 1998
    • (1998) Cancer Res , vol.58 , pp. 60-64
    • Couillard, S.1    Gutman, M.2    Labrie, C.3    Belanger, A.4    Candas, B.5    Labrie, F.6
  • 209
    • 0030711496 scopus 로고    scopus 로고
    • Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800
    • Sourla A, Luo S, Labrie C, Belanger A, Labrie F: Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology 138: 5605-5617, 1997
    • (1997) Endocrinology , vol.138 , pp. 5605-5617
    • Sourla, A.1    Luo, S.2    Labrie, C.3    Belanger, A.4    Labrie, F.5
  • 210
    • 0030723512 scopus 로고    scopus 로고
    • Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice
    • Luo S, Martel C, Sourla A, Gauthier S, Merand Y, Belanger A, Labrie C, Labrie F: Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer 73: 381-391, 1997
    • (1997) Int J Cancer , vol.73 , pp. 381-391
    • Luo, S.1    Martel, C.2    Sourla, A.3    Gauthier, S.4    Merand, Y.5    Belanger, A.6    Labrie, C.7    Labrie, F.8
  • 211
    • 85011457699 scopus 로고    scopus 로고
    • EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and b
    • Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguere V: EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and b. Endocrinology 139: 111-118, 1998
    • (1998) Endocrinology , vol.139 , pp. 111-118
    • Tremblay, A.1    Tremblay, G.B.2    Labrie, C.3    Labrie, F.4    Giguere, V.5
  • 214
    • 0029799612 scopus 로고    scopus 로고
    • Endometrial carcinoma
    • Rose PG: Endometrial carcinoma. N Engl J Med 335: 640-649, 1996
    • (1996) N Engl J Med , vol.335 , pp. 640-649
    • Rose, P.G.1
  • 215
  • 216
  • 217
  • 218
    • 0031928243 scopus 로고    scopus 로고
    • Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)
    • Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate 37: 51-59, 1998
    • (1998) Prostate , vol.37 , pp. 51-59
    • Rohlff, C.1    Blagosklonny, M.V.2    Kyle, E.3    Kesari, A.4    Kim, I.Y.5    Zelner, D.J.6    Hakim, F.7    Trepel, J.8    Bergan, R.C.9
  • 220
    • 0030941284 scopus 로고    scopus 로고
    • Tamoxifen-mediated growth inhibition of human cholangiocarcinoma
    • Sampson LK, Vickers SM, Ying WZ, Phillips JO: Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 57: 1743-1749, 1997
    • (1997) Cancer Res , vol.57 , pp. 1743-1749
    • Sampson, L.K.1    Vickers, S.M.2    Ying, W.Z.3    Phillips, J.O.4
  • 222
    • 0031052651 scopus 로고    scopus 로고
    • Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma
    • Gelmann EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24: S65-S70, 1997
    • (1997) Semin Oncol , vol.24
    • Gelmann, E.P.1
  • 223
    • 0029999729 scopus 로고    scopus 로고
    • Regression of large pelvic desmoid tumor by tamoxifen and sulindac
    • Izes JK, Zinman LN, Larsen CR: Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 47: 756-759, 1996
    • (1996) Urology , vol.47 , pp. 756-759
    • Izes, J.K.1    Zinman, L.N.2    Larsen, C.R.3
  • 224
    • 0031047959 scopus 로고    scopus 로고
    • Treatment of idiopathic retroperitoneal fibrosis by tamoxifen
    • Tonietto G, Agresta F, Libera DD, Bittesini L: Treatment of idiopathic retroperitoneal fibrosis by tamoxifen. Eur J Surg 163: 231-235, 1997
    • (1997) Eur J Surg , vol.163 , pp. 231-235
    • Tonietto, G.1    Agresta, F.2    Libera, D.D.3    Bittesini, L.4
  • 225
    • 0030593681 scopus 로고    scopus 로고
    • ERb: Identification and characterization of a novel human estrogen receptor
    • Mosselman S, Polman J, Dijkema R: ERb: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996
    • (1996) FEBS Lett , vol.392 , pp. 49-53
    • Mosselman, S.1    Polman, J.2    Dijkema, R.3
  • 227
    • 0032481256 scopus 로고    scopus 로고
    • The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro
    • Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126, 1998
    • (1998) Biochem Biophys Res Commun , vol.243 , pp. 122-126
    • Ogawa, S.1    Inoue, S.2    Watanabe, T.3    Hiroi, H.4    Orimo, A.5    Hosoi, T.6    Ouchi, Y.7    Muramatsu, M.8
  • 228
    • 0030747070 scopus 로고    scopus 로고
    • Mwse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a
    • Pettersson K, Grandien K, Kuiper GGJM, Gustafsson JA: Mwse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a. Mol Endocrinol 11: 1486-1496, 1997
    • (1997) Mol Endocrinol , vol.11 , pp. 1486-1496
    • Pettersson, K.1    Grandien, K.2    Kuiper, G.G.J.M.3    Gustafsson, J.A.4
  • 229
    • 0030738318 scopus 로고    scopus 로고
    • The novel estrogen receptor-b subtype: Potential role in the cell- And promoter-specific actions of estrogens and anti-estrogens
    • Kuiper GGJM, Gustafsson JA: The novel estrogen receptor-b subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410: 87-90, 1997
    • (1997) FEBS Lett , vol.410 , pp. 87-90
    • Kuiper, G.G.J.M.1    Gustafsson, J.A.2
  • 230
    • 0030752456 scopus 로고    scopus 로고
    • Estrogen receptors a and b form heterodimers on DNA
    • Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors a and b form heterodimers on DNA. J Biol Chem 272: 19858-19862, 1997
    • (1997) J Biol Chem , vol.272 , pp. 19858-19862
    • Cowley, S.M.1    Hoare, S.2    Mosselman, S.3    Parker, M.G.4
  • 231
    • 0031816540 scopus 로고    scopus 로고
    • Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonist-slantagonists
    • Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonist-slantagonists. Mol Pharnacol 54: 105-112, 1998
    • (1998) Mol Pharnacol , vol.54 , pp. 105-112
    • Barkhem, T.1    Carlsson, B.2    Nilsson, Y.3    Enmark, E.4    Gustafsson, J.A.5    Nilsson, S.6
  • 234
    • 0033083821 scopus 로고    scopus 로고
    • Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins
    • Dotzlaw H, Leygue E, Watson PH, Murphy LC: Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59: 529-532, 1999
    • (1999) Cancer Res , vol.59 , pp. 529-532
    • Dotzlaw, H.1    Leygue, E.2    Watson, P.H.3    Murphy, L.C.4
  • 235
    • 0031791153 scopus 로고    scopus 로고
    • Identification of estrogen receptor b2, a functional variant of estrogen receptor b expressed in normal rat tissues
    • Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA: Identification of estrogen receptor b2, a functional variant of estrogen receptor b expressed in normal rat tissues. Endocrinology 139: 1082-1092, 1998
    • (1998) Endocrinology , vol.139 , pp. 1082-1092
    • Petersen, D.N.1    Tkalcevic, G.T.2    Koza-Taylor, P.H.3    Turi, T.G.4    Brown, T.A.5
  • 236
    • 0033559575 scopus 로고    scopus 로고
    • Expression of estrogen receptor beta 1, beta 2, and beta 5 messenger RNAs in human breast tissue
    • Leygue E, Dotzlaw H, Watson PH, Murphy LC: Expression of estrogen receptor beta 1, beta 2, and beta 5 messenger RNAs in human breast tissue. Cancer Res 59: 1175-1179, 1999
    • (1999) Cancer Res , vol.59 , pp. 1175-1179
    • Leygue, E.1    Dotzlaw, H.2    Watson, P.H.3    Murphy, L.C.4
  • 237
    • 0023573087 scopus 로고
    • Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma ceil proliferation
    • Fontana JA: Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma ceil proliferation. Exp Cell Biol 55: 136-144, 1987
    • (1987) Exp Cell Biol , vol.55 , pp. 136-144
    • Fontana, J.A.1
  • 238
    • 0024321412 scopus 로고
    • Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
    • Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49: 4472-4476, 1989
    • (1989) Cancer Res , vol.49 , pp. 4472-4476
    • Ratko, T.A.1    Detrisac, C.J.2    Dinger, N.M.3    Thomas, C.F.4    Kelloff, G.J.5    Moon, R.C.6
  • 239
    • 0032006028 scopus 로고    scopus 로고
    • Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
    • Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 58: 479-484, 1998
    • (1998) Cancer Res , vol.58 , pp. 479-484
    • Bischoff, E.D.1    Gottardis, M.M.2    Moon, T.E.3    Heyman, R.A.4    Lamph, W.W.5
  • 242
    • 0031838157 scopus 로고    scopus 로고
    • Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids
    • Toma S, Isnardi L, Riccardi L, Bollag W: Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18: 935-942, 1998
    • (1998) Anticancer Res , vol.18 , pp. 935-942
    • Toma, S.1    Isnardi, L.2    Riccardi, L.3    Bollag, W.4
  • 244
    • 0032555196 scopus 로고    scopus 로고
    • Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
    • Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 8806-8811
    • Elstner, E.1    Muller, C.2    Koshizuka, K.3    Williamson, E.A.4    Park, D.5    Asou, H.6    Shintaku, P.7    Said, J.W.8    Heber, D.9    Koeffler, H.P.10
  • 246
    • 0032146179 scopus 로고    scopus 로고
    • 19-nor-26,27-bishomo-vitamin D-3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells
    • Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler NP: 19-nor-26,27-bishomo-vitamin D-3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58: 3370-3375, 1998
    • (1998) Cancer Res , vol.58 , pp. 3370-3375
    • Kubota, T.1    Koshizuka, K.2    Koike, M.3    Uskokovic, M.4    Miyoshi, I.5    Koeffler, N.P.6
  • 247
    • 0032230284 scopus 로고    scopus 로고
    • Estrogen receptor, a common interaction partner for a subset of nuclear receptors
    • Lee SK, Choi HS, Song MR, Lee MO, Lee JW: Estrogen receptor, a common interaction partner for a subset of nuclear receptors. Mol Endocrinol 12: 1184-1192, 1998
    • (1998) Mol Endocrinol , vol.12 , pp. 1184-1192
    • Lee, S.K.1    Choi, H.S.2    Song, M.R.3    Lee, M.O.4    Lee, J.W.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.